Literature DB >> 12506013

Opposing effects of PML and PML/RAR alpha on STAT3 activity.

Akira Kawasaki1, Itaru Matsumura, Yoshihisa Kataoka, Eri Takigawa, Koichi Nakajima, Yuzuru Kanakura.   

Abstract

Promyelocytic leukemia protein PML acts as a tumor suppressor, whereas its chimeric mutant promyelocytic leukemia/retinoic acid receptor alpha (PML/RAR alpha) causes acute promyelocytic leukemia (APL). Because PML has been shown to form transcription-regulatory complexes with various molecules, we speculated that PML and/or PML/RAR alpha might affect signal transducer and activator of transcription 3 (STAT3) activity, which plays a crucial role in granulocyte colony-stimulating factor (G-CSF)-induced growth and survival of myeloid cells. In luciferase assays, PML inhibited STAT3 activity in NIH3T3, 293T, HepG2, and 32D cells. PML formed a complex with STAT3 through B-box and COOH terminal regions in vitro and in vivo, thereby inhibiting its DNA binding activity. Although PML/RAR alpha did not interact with STAT3, it dissociated PML from STAT3 and restored its activity suppressed by PML. To assess the biologic significance of these findings, we introduced PML and PML/RAR alpha into interleukin-3 (IL-3)-dependent Ba/F3 cells expressing the chimeric receptor composed of extracellular domain of G-CSF-R and cytoplasmic domain of gp130, in which gp130-mediated growth is essentially dependent on STAT3 activity. Neither PML nor PML/RAR alpha affected IL-3-dependent growth of these clones. By contrast, gp130-mediated growth was abrogated by PML, whereas it was enhanced by PML/RAR alpha. These results reveal new functions of PML and PML/RAR alpha and suggest that dysregulated STAT3 activity by PML/RAR alpha may participate in the pathogenesis of APL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12506013     DOI: 10.1182/blood-2002-08-2474

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Cellular senescence and protein degradation: breaking down cancer.

Authors:  Xavier Deschênes-Simard; Frédéric Lessard; Marie-France Gaumont-Leclerc; Nabeel Bardeesy; Gerardo Ferbeyre
Journal:  Cell Cycle       Date:  2014-05-27       Impact factor: 4.534

Review 2.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

3.  The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling.

Authors:  Youn-Hee Choi; Rosa Bernardi; Pier Paolo Pandolfi; Etty N Benveniste
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-22       Impact factor: 11.205

4.  Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.

Authors:  Kuo-Sheng Hsu; Xuan Zhao; Xiwen Cheng; Dongyin Guan; Ganapati H Mahabeleshwar; Yu Liu; Ernest Borden; Mukesh K Jain; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

5.  PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.

Authors:  Hong-Yi Kuo; Yen-Sung Huang; Chin-Hsiu Tseng; Yi-Chen Chen; Yu-Wei Chang; Hsiu-Ming Shih; Cheng-Wen Wu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.

Authors:  Siqing Wang; Guido Tricot; Lei Shi; Wei Xiong; Zhaoyang Zeng; Hongwei Xu; Maurizio Zangari; Bart Barlogie; John D Shaughnessy; Fenghuang Zhan
Journal:  Blood       Date:  2009-05-20       Impact factor: 22.113

Review 7.  Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?.

Authors:  Bharat B Aggarwal; Ajaikumar B Kunnumakkara; Kuzhuvelil B Harikumar; Shan R Gupta; Sheeja T Tharakan; Cemile Koca; Sanjit Dey; Bokyung Sung
Journal:  Ann N Y Acad Sci       Date:  2009-08       Impact factor: 5.691

8.  Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumor-infiltrating lymphocytes.

Authors:  Hee Ja Kim; Dong Eun Song; Seul Ye Lim; Sung-Hee Lee; Jihee Lee Kang; Sun Jung Lee; Etty N Benveniste; Youn-Hee Choi
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

9.  Post-translational modifications of PML: consequences and implications.

Authors:  Xiwen Cheng; Hung-Ying Kao
Journal:  Front Oncol       Date:  2013-01-04       Impact factor: 6.244

10.  Targeting PML-RARα and Oncogenic Signaling Pathways by Chinese Herbal Mixture Tien-Hsien Liquid in Acute Promyelocytic Leukemia NB4 Cells.

Authors:  Chih-Jung Yao; Chia-Ming Yang; Shuang-En Chuang; Jiann-Long Yan; Chun-Yen Liu; Suz-Wen Chen; Kun-Huang Yan; Tung-Yuan Lai; Gi-Ming Lai
Journal:  Evid Based Complement Alternat Med       Date:  2011-02-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.